Press room | News



Apr 28, 2016

Heptares CSO and Co-founder - Dr Fiona Marshall - Elected as a Fellow of The Academy of Medical Sciences

Apr 25, 2016

Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors enabling Structure-Based Design for Metabolic Disease

Apr 18, 2016

Heptares and Kymab enter Strategic Collaboration to Discover, Develop and Commercialise Novel Antibody Therapeutics

Apr 6, 2016

Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer’s and Other Neurological Disorders

Apr 4, 2016

Heptares Joins Pharma Consortium Applying State-of-the-Art Cryo-Electron Microscopy to Advance Structure-Based Drug Discovery

Feb 10, 2016

Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-In-Class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

Feb 2, 2016

Heptares Launches “ORBIT” Initiative - A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRs)

Nov 30, 2015

Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. focused on GPCR Targets across Multiple Therapeutics Areas

Nov 25, 2015

Teva and Heptares Enter Agreement to Discover and Develop Novel, Small-Molecule CGRP Antagonists for Treatment of Migraine

Oct 2, 2015

Heptares wins Best UK Biotech Dealmaker Award at OBN Annual Awards 2015

Sep 28, 2015

Heptares Awarded $5.5 Million Research & Development Grant from the US National Institute on Drug Abuse (NIDA)

Aug 17, 2015

Heptares’ Pipeline and Novel Approach to GPCR Structure-Guided Drug Discovery and Development Featured in BioCentury

Aug 6, 2015

Heptares and AstraZeneca Enter Agreement to Develop Novel Immuno-Oncology Treatments for a Range of Cancers

Jul 30, 2015

Heptares Initiates Proprietary Therapeutic Antibody Program against a GPCR Target

Jun 25, 2015

Heptares StaR® Technology and its Impact on GPCR Drug R&D featured in New Report Celebrating UK Bioscience from the UK BioIndustry Association

Jun 17, 2015

Positive Outcome of Phase 1a Study with First-Ever Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients with Alzheimer's Disease

May 22, 2015

Heptares Scientist Wins Outstanding Young Chemist Award

Feb 23, 2015

Sosei Acquires Heptares Therapeutics for up to USD 400 million

Jan 23, 2015

Heptares Scientists To Receive The Malcolm Campbell Memorial Prize For 2015 In Recognition Of Their Outstanding Contribution To GPCR Drug Discovery

Jan 22, 2015

Heptares Technology Enables Breakthrough In Drug Discovery Collaboration With AstraZeneca

Jan 8, 2015

Heptares Adds Experts In Drug Discovery And Development To Its Board Of Directors

Back to top

Other News


© 2012-2016 Heptares Therapeutics